Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Treasury Shares: 2020-2025

Historic Treasury Shares for Insight Molecular Diagnostics (IMDX) over the last 5 years, with Sep 2025 value amounting to $917,000.

  • Insight Molecular Diagnostics' Treasury Shares was N/A to $917,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $917,000, marking a year-over-year change of. This contributed to the annual value of $100,000 for FY2024, which is 1900.00% up from last year.
  • Insight Molecular Diagnostics' Treasury Shares amounted to $917,000 in Q3 2025, which was up 15.78% from $792,000 recorded in Q2 2025.
  • Over the past 5 years, Insight Molecular Diagnostics' Treasury Shares peaked at $1.5 million during Q3 2022, and registered a low of $5,000 during Q3 2023.
  • Over the past 3 years, Insight Molecular Diagnostics' median Treasury Shares value was $100,000 (recorded in 2024), while the average stood at $312,667.
  • As far as peak fluctuations go, Insight Molecular Diagnostics' Treasury Shares plummeted by 99.66% in 2023, and later surged by 15,020.00% in 2025.
  • Quarterly analysis of 5 years shows Insight Molecular Diagnostics' Treasury Shares stood at $121,000 in 2021, then crashed by 81.82% to $22,000 in 2022, then slumped by 77.27% to $5,000 in 2023, then skyrocketed by 1,900.00% to $100,000 in 2024, then skyrocketed by 15,020.00% to $917,000 in 2025.
  • Its last three reported values are $917,000 in Q3 2025, $792,000 for Q2 2025, and $756,000 during Q1 2025.